Supera Peripheral Stent System
Abbott Vascular (Idef Technologies Inc) · Decision date Feb 5, 2026
What did the FDA decide?
FDA records P120020/S035 as a supplement to PMA P120020, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 5, 2026.
FDA approval order statement
approval for a change to the outer sheath coating solution process
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Feb 5, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P120020/S035
- Regulatory pathway
- PMA supplement
- Product code
- NIP
- Decision code
- OK30
- Decision date
- Feb 5, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.
- Product code
- NIP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P120020. Subsequent supplements may change the device or its indications.
FDA decision timeline
P120020 · Original PMA
SUPERA PERIPHERAL STENT SYSTEM
P120020/S034 · Related supplement
Supera Peripheral Stent System
P120020/S035 received
Application receipt date recorded by FDA.
P120020/S035 · FDA decision
30-Day Notice
P120020/S036 · Related supplement
Supera Peripheral Stent System
P120020/S037 · Related supplement
Supera Peripheral Stent System
Timeline entries are records held by MedtechLedger for P120020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P120020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular (Idef Technologies Inc) | PMA approval | Mar 28, 2014 | FDA | |
Supera Peripheral Stent SystemP120020/S034 | Abbott Vascular (Idef Technologies Inc) | PMA supplement | Dec 9, 2025 | FDA |
Supera Peripheral Stent SystemP120020/S036 | Abbott Vascular (Idef Technologies Inc) | PMA supplement | Mar 20, 2026 | FDA |
Supera Peripheral Stent SystemP120020/S037 | Abbott Vascular (Idef Technologies Inc) | PMA supplement | Nov 6, 2026 | FDA |
Explore the linked device profile
Other records with product code NIP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Cordis US Corporation | PMA supplement | Oct 15, 2026 | FDA | |
| Biotronik AG | PMA supplement | Sep 11, 2026 | FDA | |
| BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Vascular (Idef Technologies Inc)
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3200 Lakeside Dr., Santa Clara, CA, 95054
Sources and methodology
- Original FDA record: P120020/S035
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




